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Introduction
Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE) is a public health problem. Although pharmacologic thromboprophylaxis agents (such as unfractionated heparin, low-molecular-weight heparins, warfarin, and novel oral anticoagulants) are effective, they remain underused, because they are associated with increased risk of bleeding.(1) The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (commonly known as statins), are known for their lipid-lowering properties and well established for the primary and secondary prevention of cardiovascular disease (CVD), (2) (3) (4) especially coronary heart disease. (5) Statins are also known to have pleiotropic effects that affect coagulation and inflammation, and do not increase bleeding risk. (6, 7) There is emerging evidence to suggest that through these pleiotropic effects, statins may be effective in reducing the incidence of VTE. Since the publication of the Heart and Estrogen/progestin Replacement Study (HERS), which reported an approximately 50 percent risk reduction in VTE in a nonrandomised comparison of statin versus nonstatin users, (8) several observational studies have evaluated this relationship and reported conflicting results. (9) (10) (11) (12) (13) In the first randomised controlled trial (RCT) of statins for the prevention of VTE, investigators of the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial of 17 802 participants, demonstrated that rosuvastatin significantly reduced the occurrence of all cases of VTE. (14) These results were based on relatively few VTE events suggesting a statistical play of chance and thus triggered calls for further studies to replicate these results. (15) With the publication of these studies, there have been efforts to aggregate these data over the last decade and which have resulted in a number of published reviews on the topic with inconsistent results. (16) (17) (18) (19) In analysis of eight case-control studies and three cohort studies, Squizzato and colleagues showed no evidence of a significant reduction in VTE with statin use, when the results were pooled by study design; however, pooled analysis of all studies (including the JUPITER trial) showed a significant reduction in risk of VTE. (17) In a meta-analysis of 29 RCTs published in 2012, Rahimi and colleagues found no significant reduction in VTE events with statin therapy. (19) Indeed, the existing evidence shows there is still uncertainty regarding the effect of statins on VTE outcomes. In addition, there were several features of these previous reviews which limited the generalisability and validity of the findings. First, majority of these previous reviews (except for the study by Rahimi and colleagues (19) ) pooled a limited number of studies which did not provide adequate power to evaluate the associations. Second, several of these reviews pooled results of different study designs making interpretation of the findings difficult. Third, these previous reviews did not conduct detailed exploration of potential sources of heterogeneity among the contributing studies using formal tests such as subgroup analyses and meta-regression techniques. The topic is under considerable debate and of clinical interest as an increasing number of people are being prescribed statin therapy; and given the publication of newer studies since the last relevant meta-analysis on the topic, there is a need for further work to address the persisting uncertainties on the role of statins on VTE outcomes. In this context, we aimed to summarise the available observational and interventional evidence in one updated systematic meta-analysis. Our objectives were to (i) determine the associations of statin use with risk of first VTE outcomes in observational cohort studies; (ii) quantify the effects of statin use given alone compared with placebo (or no treatment) for the primary prevention of VTE outcomes in RCTs; and (iii) examine all associations under a wide range of relevant study level characteristics.
Methods

Data sources and search strategy
We conducted this review using a predefined protocol, which has been registered in the PROSPERO prospective register of systematic reviews (CRD42016035622), and in accordance with PRISMA and MOOSE guidelines (20, 21) (Pages 2-5 of SUPPLEMENTARY MATERIAL). Two authors independently sought studies published before July, 2016 (date last searched) using MEDLINE, EMBASE, Web of Science, and the Cochrane electronic databases. The computer-based searches combined terms related to statins (e.g., statin, hydroxymethylglutaryl-CoA reductase inhibitors, atorvastatin, simvastatin) and outcomes (e.g., venous thromboembolism, deep vein thrombosis, pulmonary embolism) in humans, without any language restriction. Details on the search strategy are provided in Page 6 of SUPPLEMENTARY MATERIAL. Two reviewers working independently screened the titles and abstracts of all initially identified studies according to the selection criteria. Full texts were retrieved from studies that satisfied all selection criteria.
Reference lists of selected studies and relevant reviews identified on the topic were manually scanned for additional publications.
Study selection and eligibility criteria
Observational cohort (prospective cohort, retrospective cohort, or nested case-control) studies were eligible for inclusion if they assessed the association of any or current statin use with first VTE, DVT, or PE event (as detected by imaging using venous ultrasonography, venography, angiography, computed tomography, ventilation and perfusion scan, or any other recognised confirmatory tests) in adults (≥ 18 years old). Intervention studies were eligible if they were randomised controlled, open or blinded trials; assessed the effects of statin therapy compared to a placebo or no treatment in adults; and collected VTE outcomes. Studies were excluded if they were non-randomised comparing statin with another statin or lipid-lowering agent or were secondary publications of trials already included in the analysis. In addition, case-control studies and studies that reported the associations between statin therapy and recurrent VTE were excluded.
Data extraction
Two authors (SKK and SS) independently extracted data and a consensus was reached in case of any inconsistency with involvement of a third (KK). We used a predesigned data extraction form to obtain relevant information. These included study-level information on study design; baseline population including proportion of men; location; average age at baseline; numbers enrolled and randomised; allocation concealment; blinding; statin type and dosage; duration of treatment or follow-up; degree of adjustment for potential confounders (defined as '+' when RRs were adjusted for age and/or sex; '++' further adjustment for established risk factors for VTE such as body mass index, history of diabetes, smoking status, exercise, alcohol consumption, immobilization, ; and '+++' additional adjustment for other potential confounders such as estrogen use or use of anticoagulants); treatment comparisons; and nature of outcome and numbers. Venous thromboembolism outcomes were extracted as reported by the eligible studies. The primary outcome of this analysis was VTE which was reported by majority of studies. Data on the specific endpoints of DVT and PE were also extracted when reported. We extracted risk estimates reported for the greatest degree of adjustment. If risk estimates were unavailable from a published report, we collected relevant data by abstracting from other published reviews or by contacting investigators of these published studies. In the case of multiple publications involving the same study, the most up-to-date or comprehensive information was abstracted.
Assessing the risk of bias
For observational cohort studies, we used the nine-star Newcastle-Ottawa Scale (NOS), (22) which is based on pre-defined criteria namely: selection (population representativeness), comparability (adjustment for confounders), and ascertainment of outcome. The NOS assigns a maximum of four points for selection, two points for comparability, and three points for outcome. Nine points on the NOS reflects the highest study quality. For RCTs, we used the Cochrane Collaboration's risk of bias tool.(23) This tool evaluates seven possible sources of bias: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting and other bias. For each individual domain, studies were classified into low, unclear and high risk of bias.
Statistical analysis
Summary measures were presented as relative risks (RRs) with 95% confidence intervals (CIs). Following Cornfield's rare disease assumption,(24) hazard ratios and odds ratios were assumed to approximate the same measure of RR. When studies published more than one estimate of the association according to subgroups (e.g., by sex, dosage), we obtained a within-study summary estimate using a fixed effect meta-analysis. The inverse variance weighted method was used to combine summary measures using random-effects models to minimise the effect of between-study heterogeneity.(25) Subsidiary analyses employed fixed effects models. Statistical heterogeneity across studies was quantified using the Cochrane χ 2 statistic and the I 2 statistic.(26) Study-level characteristics [such as geographical location, study design, baseline population (general populations versus populations with pre-existing disease or at high VTE risk), allocation concealment, statin class, statin dosage (high versus low dose), source of data (for RCTs), and study quality] were pre-specified for assessment of heterogeneity, which was conducted using stratified analyses and random effects metaregression. (27) In analysis specified post-hoc which was based on distribution of available data, further stratified analysis was conducted to examine the difference in pooled RRs by baseline average age of participants, duration of follow-up or treatment, and number of outcomes. We assessed the potential for publication bias through formal tests, namely Begg's funnel plots and Egger's regression symmetry tests.(28) All statistical tests were two-sided and used a significance level of P<0.05 and STATA release 14 (StataCorp LP, College Station, TX, USA) software was used for all statistical analyses.
Role of the funding source
There was no funding source for this study. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Results
Study identification and selection
Our initial search of relevant databases and manual scanning of reference lists identified 1125 potentially relevant citations. After screening based on titles and abstracts, 54 articles remained for full text evaluation. Following detailed assessments, 18 articles were excluded because (i) they were based on reviews (n = 8); (ii) they were case-control studies (n = 7); or evaluated recurrent outcomes (n = 3) (Pages 7-8 of SUPPLEMENTARY MATERIAL). The remaining 36 studies met our inclusion criteria and were included in the meta-analysis (figure 1; Pages 9-16 of SUPPLEMENTARY MATERIAL). Table 1 provides summary characteristics of relevant observational cohort studies and RCTs included in the metaanalysis. years. Of these observational cohort studies, eight involved participants from Europe (UK, Finland, Austria, and Netherlands), three from North America (USA and Canada), and two from Asia (Saudi-Arabia and Israel). Quality scores of the studies ranged from 5 to 8.
Study characteristics and quality
A total of 23 RCTs involving 118 464 participants and 1031 VTE outcomes were included in the review (table 1 and Pages 11-13 of SUPPLEMENTARY MATERIAL). Some baseline data and risk estimates for VTE outcomes in 20 of these trials were extracted from a published review, (19) because these data had not been reported in the original articles.
Rahimi and colleagues obtained these data from investigators of these trials and have appropriately acknowledged this in their review. We have also verified this by contacting authors of these published studies. The majority (n=17) of trials were double-blinded and six were open label trials. Majority of trials were conducted multinationally or within the European region (Scotland, Ireland, The Netherlands, Germany, and Italy). The baseline age of participants ranged from 18 to 90 years. Included trials employed different types of statin (artovastatin, fluvastatin, lovastatin, pravastatin, simvastatin, or rosuvastatin) with dosages ranging from 10 mg to 80 mg daily and the median (interquartile range) duration of follow-up was 3·9 (2·5-5·0) years. Using the Cochrane Collaboration tool, only six trials demonstrated a high risk of bias within one area of study quality, which was blinding of participants and personnel. All trials had a low risk of bias in random sequence generation and had an unclear risk of bias in one or more areas of study quality (Page 17 of SUPPLEMENTARY MATERIAL). There was considerable variability in study populations for both observational cohort studies and RCTs, which included participants recruited from general populations, participants at high vascular risk, participants with pre-existing conditions such as diabetes, heart failure, cancer, as well as renal transplant patients and patients with mild to moderate Alzheimer's disease. All studies reported on the use of statin for the primary prevention of VTE outcomes. Figure 2 presents RRs for VTE outcomes for statin use compared with no statin use in observational cohort studies contributing to pooled analysis. A significant reduction in risk of VTE was found with statin use compared with no statin use 0·75 (95% CI: 0·65 to 0·87; p<0·0001). In sensitivity analyses, the combined RR excluding the study with less than one year follow-up was 0·75 (0·65-0·87; p<0·0001), which was identical to the main finding.
Association of statin use with VTE in prospective cohort studies
There was evidence of substantial heterogeneity between the contributing studies (I 2 =82%, 70 to 89%; p<0·0001) which was partly explained by several study level characteristics such as geographical location (p for meta-regression = 0·014), study design (p for meta-regression = 0·001), baseline population (p for meta-regression < 0·0001), study size (p for metaregression < 0·0001), and study quality (p for meta-regression = 0·026). A stronger association was observed in populations with pre-existing disease or at high VTE risk 0·46 (95% CI: 0·25 to 0·83; p=0·010) compared to studies that recruited participants from the general population 0·86 (95% CI: 0·80 to 0·92; p<0·0001) (figure 3). In further exploration of heterogeneity, this was substantially reduced when pooled analysis was limited to prospective cohort designs (I 2 =58%, 8 to 81%; p=0·020) and the pooled result was attenuated but a protective association was still evident 0·88 (0·81-0·96; p=0·004). Similar results were observed when analysis was limited to studies that recruited participants from general populations.
Statin use compared to no statin use was also associated with a significant reduction in risk of the specific endpoint of DVT 0·77 (95% CI: 0·69 to 0·86; p<0·0001). There was no evidence of heterogeneity between the two studies included in this analysis. In one study reporting PE outcomes, the RR for PE comparing statin use with no statin use was 1·02 (95% CI: 0·74 to 1·40; p=0·90).
Effects of statin therapy on VTE in randomised controlled trials
Statin therapy compared with placebo or no treatment, was associated with a significant reduction in risk of VTE events in pooled analysis of 23 trials 0·85 (95% CI: 0·73 to 0·99; p=0·038) ( figure 4 ). There was no evidence of substantial heterogeneity between the contributing studies (I 2 =13%, 0 to 47%; p=0·28). The pooled RR remained unchanged using a fixed effects model 0·85 (95% CI: 0·73 to 0·99; p=0·032). In subgroup analyses, the effect of statin therapy on VTE risk did not vary significantly across several study level characteristics, except for by statin class (p for meta-regression = 0·015). Populations on rosuvastatin therapy had a significant reduction in VTE events compared to other statins. The risk of VTE was statistically significantly reduced for general populations compared to populations with pre-existing disease or at high risk of VTE. Similarly, compared to high dose artovastatin or rosuvastatin, low doses of each of these statins were associated with a statistically significant reduced risk of VTE ( figure 5 ). In the single largest trial that also reported results for the specific endpoints of DVT and PE; whiles a significant reduction in risk of DVT was found for statin therapy, there was no significant effect on PE (figure 4).
Publication bias
Under visual examination, funnel plots for both observational cohort studies and RCTs were symmetrical and Egger's regression tests showed no statistical evidence of publication bias (Page 18 of SUPPLEMENTARY MATERIAL).
Discussion
Key findings
The findings of this review indicate a protective effect of statin use in the primary prevention of VTE in both observational cohort and intervention studies. The inverse association demonstrated in observational studies remained consistent across several study level subgroups. In RCTs, there was suggestion of effect modification in stratified analyses by type of statin. Rosuvastatin therapy substantially and significantly reduced VTE risk, with no benefit seen with other statins. There was no evidence of a protective effect of statins on the specific outcome of PE in both observational cohort and intervention studies.
Comparison with previous work
A number of reviews have been conducted on the topic and some of our findings concur with those of these previous reviews. In a meta-analysis of 10 studies (comprising one RCT and a mixture of case-control, retrospective, and prospective cohort studies), Agarwal and colleagues reported a decreased risk of VTE outcomes with statin use.(16) Pai and colleagues in pooled analysis of four case-control and four cohort studies showed a statistically significant reduction in risk of VTE. (18) In agreement with the results of these previous reviews, our pooled analysis of observational studies demonstrated a significant reduction in risk of VTE. However, our updated review of observational cohort studies also provides several important findings that have not been previously reported. Based on inclusion of additional studies, we had enhanced power to examine the associations in greater depth, such as the detailed exploration of sources of heterogeneity using a broader range of individual and study level circumstances. Our analyses suggested differences in the effect of statin use on VTE events by characteristics such as geographical location, study design, baseline population, and study size. Our review of RCTs provide several relevant findings that were not previously reported by the last relevant review published on the topic. (19) We found a significant reduction in VTE in pooled analysis of 23 RCTs of statin therapy compared with placebo or no treatment. Stratified analyses by several study level characteristics suggested evidence of effect modification by statin type, with rosuvastatin showing a beneficial effect on VTE compared to other statins. There were also suggestions of differences in the effect of statin on VTE by baseline population and statin dose; however, there was no statistically significant evidence of effect modification in these analyses.
Possible explanations for findings
The statistically significant findings in our pooled analyses of RCTs are not in stark contrast to findings of Rahimi and colleagues. (19) The risk estimate reported in the previous review was consistent with a potential benefit of statin on VTE, but was on the verge of statistical significance. This could be attributed to low power to detect an effect. The addition of results Whether VTE reduction is a class effect of statins is uncertain given the existing limited and inconsistent evidence. (12, 40) In our subgroup analyses of RCTs, we found evidence suggesting a difference in the effect of statin on VTE by type of statin, with rosuvastatin having a significant beneficial effect on risk of VTE compared to other statins. However, given that we were unable to conduct a head-to-head comparison of the statins and the limited number of studies available for such subgroup analyses, these findings may have arisen from the effects of low statistical power or chance. Further investigation is therefore needed to replicate and validate these results.
Implications of our findings
Several implications exist for our findings. Based on both observational and clinical trial evidence, these findings underscore a potential beneficial role of statin therapy on VTE in addition to its established role in CVD prevention. The results also suggest that this effect of statins may be attributed to rosuvastatin. Currently, statins are only approved for lipid lowering in the primary and secondary prevention of CVD; (41) Further investigation is also required to evaluate the putative preventive effect of statins in VTE recurrence.
Strengths and limitations
Our systematic review and meta-analysis has several strengths in comparison to previous reviews and these deserve mention. Our review included analyses of observational evidence as well as clinical trial data in a single investigation; thus providing the most comprehensive update on the effect of statin therapy on VTE. Our search strategy was very detailed, was without language restriction, and spanned multiple databases. Most of our trial evidence was based on unpublished data which was recently published by a recent elegant review. (19) Indeed, formal tests showed no evidence of publication bias in our analyses. The generalisability of our findings was enhanced by the involvement of data from 13 observational studies and 23 RCTs, making it the largest review to date on the topic. There was enhanced power, therefore the ability to quantify more reliably the magnitude of the associations as well as conduct detailed analyses under a wider range of study-level circumstances. Given the data available, we were able to systematically explore possible sources of heterogeneity using stratified and meta-regression analyses. A detailed assessment of methodological quality of the included studies was conducted; observational cohort studies were all of adequate quality and majority of the intervention studies had low risk of bias. In our review of observational evidence, we included only observational cohorts, which offsets some of the biases inherent in cross-sectional and case-control studies and decreases the likelihood of reverse causality. Finally, our results remained robust in several sensitivity analyses. There are several limitations which also deserve consideration. First, owing to the small number of studies (both observational studies and RCTs) for the outcomes of DVT and PE, this precluded inadequate assessment of the impact of statin use or therapy on each of these endpoints. Second, due to the limited data available for subgroup analyses by statin type in both study designs, we were unable to adequately explore whether the effect of statins on VTE was a class effect. Third, we pooled estimates from both retrospective and prospective cohort designs as well studies that included people from the general population and those at high risk of thrombotic events, which could have potentially led to biased estimates. The lack of appropriate data precluded the ability to compare the protective effect of statins in participants with normal cholesterol levels to those with hypercholesterolemia. However, our results of a subgroup analyses by the type of study design and baseline population showed a protective effect of statin use on VTE in all groups. Fourth, we were unable to conduct a subgroup analysis by type of VTE (provoked versus unprovoked) because of limited data provided by eligible studies. Fifth, as with aggregate data, pooled analysis of observational cohorts was based on variably adjusted data reported by the eligible studies, thereby increasing the possibility of residual confounding. However, all studies adjusted for a comprehensive panel of biological markers and lifestyle characteristics. Sixth, there was substantial heterogeneity between observational studies, however possible sources of this were systematically explored using stratified and meta-regression analyses. There was however no significant evidence of heterogeneity between the contributing trials. Finally, given that our trial evidence was mostly based on previously unpublished data (with VTE collected as adverse events) contributed by investigators, this could have potentially led to biased estimates in our analyses. However, a subgroup analysis comparing pooled estimates from previously unpublished data to published data (where VTE was pre-specified as an outcome) showed no evidence of effective modification. Given the limitations, the findings should be interpreted with caution and intensify the need for detailed future intervention studies with VTE pre-specified as primary outcomes and individual patient data meta-analysis to help establish the beneficial role of statins in the prevention of VTE. 
Conclusions
Research in context
Evidence before this study
The lipid-lowering properties of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (commonly known as statins) and their effectiveness for the primary and secondary prevention of cardiovascular disease (CVD) are well established. Statins are currently only approved for lipid lowering in the primary and secondary prevention of CVD. Relevant prospective cohort studies conducted in general populations and randomised controlled trials (RCTs) reporting on associations between statins and venous thromboembolism (VTE) (including deep vein thrombosis and pulmonary embolism) were sought from MEDLINE, EMBASE, Web of Science, and Cochrane Library; with particular emphasis on systematic reviews and metaanalyses of these study designs. We used the search terms "statin", "hydroxymethylglutaryl-CoA reductase inhibitors" and "venous thromboembolism", "deep vein thrombosis", "pulmonary embolism". Several observational studies were found to have evaluated the relationship, but the results were conflicting. A limited number of RCTs demonstrated that statins reduced the occurrence of VTE, but these results were based on few VTE events, which suggested a statistical play of chance. Previous reviews on the topic have also reported inconsistent results. Statins may have a protective effect on the incidence of VTE, however, the overall evidence is uncertain.
Added value of this study
This meta-analysis of observational and intervention studies suggest a beneficial effect of statin therapy on venous thromboembolism. In observational studies, the protective effect of statins on risk of VTE remained consistent when grouped by various study level characteristics. In intervention studies, rosuvastatin therapy substantially and significantly reduced the risk of venous thromboembolism risk, with no benefit seen with other statins.
Implications of all the available evidence
Based on both observational and clinical trial evidence, these findings underscore a potential beneficial role of statin therapy on VTE in addition to its established role in CVD prevention.
The results also suggest that this effect of statins may be attributed to rosuvastatin. Prevention of VTE may be another potential indication of statins; however, before any guideline recommendations should be made, further research is needed to unequivocably establish this potential true protective effect. 
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